TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Phil Nadeau has given his Buy rating due to a combination of factors related to Voyager Therapeutics’ promising pipeline and financial stability. The company reported a strong cash position of $262 million, which is expected to support its operations until 2028, providing a solid financial foundation for its ongoing and future projects.
Voyager is making significant progress in its clinical programs, particularly with its VY7523 anti-tau antibody for Alzheimer’s disease, which is in the final cohort of its Phase I trial. Additionally, the collaboration with Neurocrine Biosciences on gene therapy programs for GBA1 and FXN is advancing, with Investigational New Drug applications anticipated in 2025. The company’s strategic initiatives, including the development of a new Alzheimer’s therapy leveraging its TRACER capsid technology, further enhance its potential for future growth and innovation.
In another report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $12.00 price target.